Onco-hematology Molecular Testing Market Key Players Analysis - Asuragen, Inc., Bio-Rad Laboratories, Inc., ICON plc, Illumina, Inc., Integrated DNA Technologies.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Onco-hematology Molecular Testing Market- (By Blood Cancer Type, (Chronic Myeloid Leukemia, (Polycythemia Vera, Essential, Thrombocythaemia, Myelofibrosis), Myeloproliferative Neoplasms, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia), By Technology (qPCR, dPCR, Next-Generation Sequencing, Others), By Blood Cancer Biomarker(BCR-ABL1 Mbcr, JAK2, CALR, MPL, PML-RARA, NPM1, RUNX1-RUNX1T1, CBFB-MYH11, BCR-ABL1 mbcr), By End-user (National Reference Lab / Specialty Lab, University Hospital / Oncology Center, Community Hospital / IDN (Regional/National))) Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Onco-hematology Molecular Testing Market is valued at US$ 497.67 Mn in 2022, and it is expected to reach US$ 1280.06 Mn by 2031, with a CAGR of 11.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1995

Hemato-oncology is a specialized medical discipline dedicated to the diagnosis, treatment, and prevention of blood-related disorders, including malignancies such as lymphoma and myeloma. The increasing incidence of these cancers is anticipated to significantly contribute to the growth of the market over the forecast period. According to the American Cancer Society, Non-Hodgkin lymphoma (NHL) represents one of the most frequently diagnosed cancers in the United States, accounting for approximately 4.0% of all cancer cases.

Molecular diagnostics in oncology focus on the analysis of biological molecules within cancer cells to facilitate the detection, classification, and monitoring of cancer. This approach involves the identification and quantification of specific genetic sequences within DNA, RNA, and associated cellular proteins, typically through diagnostic tests conducted on blood, saliva, or tissue samples obtained from tumors. These molecular tools provide comprehensive and rapid insights that support the development of personalized treatment strategies for cancer patients.

Such diagnostics are utilized in both point-of-care (POC) settings and within broader clinical testing frameworks for cancer detection. In addition, blood banks employ molecular diagnostic technologies to screen blood samples for the presence of infectious agents and pathogens, further supporting their role in enhancing transfusion safety and public health.

List of Prominent Players in the Onco-hematology Molecular Testing Market:
• Asusragen, Inc.
• Bio-Rad Laboratories, Inc.
• ICON plc
• Illumina, Inc.
• Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
• Invivoscribe, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Cepheid

Market Dynamics:
Drivers-
The global oncology molecular diagnostics market is expected to experience significant growth due to several factors, including the increasing prevalence of various cancers, the shift toward precision medicine, growing demand for preventive care, the adoption of advanced and automated cancer diagnostic techniques, and favorable health reimbursement policies. According to the World Health Organization, an estimated 18.0 million new cancer cases were diagnosed globally in 2018, a figure that is expected to further accelerate the growth of the oncology molecular diagnostics market. However, challenges such as the high costs associated with molecular diagnostics, budgetary constraints, and the need for specialized facilities may hinder the market's expansion.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Challenges:
The global allocation of hospital resources for oncology care faced significant disruptions during the COVID-19 pandemic. According to a study published in Haematological Oncology in October 2022, the pandemic severely impacted the management of lymphoma and other hematologic malignancies across various regions, placing increased strain on healthcare systems and potentially compromising patient outcomes. Furthermore, research published in the Journal of Clinical Oncology in September 2022 documented a 22% decline in new diagnoses of multiple myeloma in the United States during the early phase of the pandemic. Despite these setbacks, the latter stages of the pandemic witnessed a resurgence in demand for cancer diagnostics, particularly for hematologic cancers, as healthcare systems began to recover and address the backlog of cases.

Regional Trends:
North America continues to be a key contributor to the global hematologic cancer diagnostics market, supported by a high disease burden, growing geriatric population, increased awareness of innovative treatment modalities, and the strong presence of major industry stakeholders. The region's leadership in the market is reinforced by the rising prevalence of blood cancers such as leukemia, lymphoma, and multiple myeloma. For instance, data from the Canadian Cancer Society indicated that in 2021, approximately 6,700 new leukemia cases were reported in Canada, with 4,000 diagnoses among men and 2,700 among women, underscoring the ongoing need for advanced diagnostic and treatment solutions.

Recent Developments:
• In Mar 2023, Servier and QIAGEN partnered to create a new mIDH1 companion diagnostic test to help Servier's onco-hematology portfolio. This test was used with Servier's tailored treatments for Acute Myeloid Leukaemia (AML) that were on the market and still being researched.
• In Apr 2021, Kartos Therapeutics and Illumina announced a new oncology partnership to create a TP53 companion diagnostic based on NGS. The TSO 500 with peripheral whole blood as a diagnostic sample type was first used in this companion diagnostic for various hematologic purposes.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1995

Segmentation of Onco-hematology Molecular Testing Market-
• Blood Cancer Type
o Chronic Myeloid Leukemia
 Polycythemia Vera
 Essential Thrombocythaemia
 Myelofibrosis
o Myeloproliferative Neoplasms
o Acute Myeloid Leukemia
o Acute Lymphoblastic Leukemia
• Technology
o qPCR
o dPCR
o Next-Generation Sequencing
o Others
• Blood Cancer Biomarker
o BCR-ABL1 Mbcr
o JAK2
o CALR
o MPL
o PML-RARA
o NPM1
o RUNX1-RUNX1T1
o CBFB-MYH11
o BCR-ABL1 mbcr
• End-user
o National Reference Lab / Specialty Lab
o University Hospital / Oncology Center
o Community Hospital / IDN (Regional/National)
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/onco-hematology-molecular-testing-market/1995

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.